i.c.v. delivery of AAV9-synapsin-promoted caveolin-1 attenuates neuromuscular deficits and neuromuscular degeneration in hSOD1<sup>G93A</sup> mice.
Overview
- Department of Anesthesiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA 92093, USA
- VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
- Department of Neurosurgery, Institute of Medicine, University of Tsukuba, 1-1-1- Tennodai, Tsukuba, Ibaraki 305-8575, Japan
Abstract
Practical and broad biodistributable gene delivery interventions are essential for advancing therapeutic strategies targeting neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). We previously demonstrated that subpial delivery of AAV9-synapsin-promoted caveolin-1 (SynCav1) afforded significant neuroprotective effects in mutant superoxide dismutase (SOD)-1-induced ALS pathology. However, subpial delivery is regionally restricted, technically challenging, and highly invasive. This study evaluated whether the intracerebroventricular (i.c.v.) route of administration (ROA), an alternative CNS delivery strategy less invasive than direct spinal cord injections, could achieve broader CNS biodistribution and produce functional or histological benefits in hSOD1G93A mice. i.c.v. administration of AAV9-SynCav1 achieved widespread Cav-1 overexpression in the motor cortex and spinal cord. SynCav1-treated male mice exhibited improved running wheel (RW) performance and better motor-evoked potentials. Immunofluorescence revealed attenuated degeneration of cholinergic motor neurons (MNs) in the cervical and lumbar ventral horn, as well as preserved diaphragm neuromuscular junction (NMJ) innervation in SynCav1-treated mice. These findings serve as preclinical proof of concept that i.c.v. delivery of AAV9-SynCav1 can achieve CNS target engagement and produce selective functional and anatomical benefits in hSOD1G93A mice.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.
The paper's code and data availability statement is in the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.
Data
No dataset and no data link were found in the paper.
Data and code availability
The data that support findings of this study are available within this study or available from the corresponding author (B.P.H.) upon reasonable request.
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 2, 28 September 2026
- Authors: added Noriyuki Watanabe (0000-0001-5941-3369); Brian P. Head (0000-0001-9417-5351); removed Noriyuki Watanabe; Brian P. Head
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 9 authors, 6 keywords, 5 funders, 44 references.
Cite
This paper
Watanabe, N., Kawahori, Y., Ta, V., Wang, D., Ohgi, K. A., Wang, H., Kleschevnikova, N., Ishikawa, E., & Head, B. P. (2026). i.c.v. delivery of AAV9-synapsin-promoted caveolin-1 attenuates neuromuscular deficits and neuromuscular degeneration in hSOD1&
BibTeX
@article{watanabe2026i,
author = {Watanabe, Noriyuki and Kawahori, Yumi and Ta, Vinh and Wang, Dongsheng and Ohgi, Kenneth A. and Wang, Hongxia and Kleschevnikova, Natalia and Ishikawa, Eiichi and Head, Brian P.},
title = {{i.c.v. delivery of AAV9-synapsin-promoted caveolin-1 attenuates neuromuscular deficits and neuromuscular degeneration in hSOD1\&
journal = {Molecular therapy. Advances},
year = {2026},
month = jul,
volume = {34},
number = {3},
pages = {201820},
publisher = {American Society of Gene \& Cell Therapy},
issn = {3117-387X},
doi = {10.1016/
url = {https://
pmid = {42614372},
pmcid = {PMC13481751}
}
RIS
TY - JOUR
AU - Watanabe, Noriyuki
AU - Kawahori, Yumi
AU - Ta, Vinh
AU - Wang, Dongsheng
AU - Ohgi, Kenneth A.
AU - Wang, Hongxia
AU - Kleschevnikova, Natalia
AU - Ishikawa, Eiichi
AU - Head, Brian P.
TI - i.c.v. delivery of AAV9-synapsin-promoted caveolin-1 attenuates neuromuscular deficits and neuromuscular degeneration in hSOD1&
T2 - Molecular therapy. Advances
J2 - Mol Ther Adv
PY - 2026
DA - 2026/
VL - 34
IS - 3
SP - 201820
SN - 3117-387X
PB - American Society of Gene & Cell Therapy
DO - 10.1016/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1016/
"type": "article-journal",
"title": "i.c.v. delivery of AAV9-synapsin-promoted caveolin-1 attenuates neuromuscular deficits and neuromuscular degeneration in hSOD1&
"container-title": "Molecular therapy. Advances",
"author": [
{
"family": "Watanabe",
"given": "Noriyuki"
},
{
"family": "Kawahori",
"given": "Yumi"
},
{
"family": "Ta",
"given": "Vinh"
},
{
"family": "Wang",
"given": "Dongsheng"
},
{
"family": "Ohgi",
"given": "Kenneth A."
},
{
"family": "Wang",
"given": "Hongxia"
},
{
"family": "Kleschevnikova",
"given": "Natalia"
},
{
"family": "Ishikawa",
"given": "Eiichi"
},
{
"family": "Head",
"given": "Brian P."
}
],
"container-title-short":
"volume": "34",
"issue": "3",
"page": "201820",
"DOI": "10.1016/
"PMID": "42614372",
"PMCID": "PMC13481751",
"ISSN": "3117-387X",
"publisher": "American Society of Gene & Cell Therapy",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
27
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1016/j.omta.2026.201818
- Antisense oligonucleotide treatment following viral delivery of artificial SOD1-targeting miRNA shows improved efficacy in SOD1-G93A mice.Journal: Molecular therapy. AdvancesIn common: other condition, mouse, 6 references
- [2] doi:10.1038/s44321-024-00148-5
- Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47.Journal: EMBO molecular medicineIn common: mouse, 5 references
- [3] doi:10.1073/pnas.2418024121
- Cis-regulatory elements driving motor neuron-selective viral payload expression within the mammalian spinal cord.Journal: Proceedings of the National Academy of Sciences of the United States of AmericaIn common: mouse, 4 references
- [4] doi:10.1186/s40478-022-01376-x
- The distribution and function of GDE2, a regulator of spinal motor neuron survival, are disrupted in Amyotrophic Lateral Sclerosis.Journal: Acta neuropathologica communicationsIn common: other condition, mouse, 4 references
- [5] doi:10.3389/fncel.2023.1112405
- Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival.Journal: Frontiers in cellular neuroscienceIn common: other condition, 3 references
- [6] doi:10.1038/s41392-025-02258-z
- Neuron-targeted caveolin-1 overexpression attenuates cognitive loss and pathological transcriptome changes in symptomatic Alzheimer's disease models.Journal: Signal transduction and targeted therapyIn common: mouse, 3 references
- [7] doi:10.1093/braincomms/fcac145
- Prionoids in amyotrophic lateral sclerosis.Journal: Brain communicationsIn common: other condition, 3 references
- [8] doi:10.1038/s41467-024-48974-y
- Engineering viral vectors for acoustically targeted gene delivery.Journal: Nature communicationsIn common: mouse, 3 references
- [9] doi:10.3389/fnins.2023.1170996
- Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy.Journal: Frontiers in neuroscienceIn common: other condition, 3 references
- [10] doi:10.1016/j.ymthe.2025.03.057
- Current trends in gene therapy to treat inherited disorders of the brain.Journal: Molecular therapy : the journal of the American Society of Gene TherapyIn common: 3 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
